Therapeutic vaccines for tuberculosis—A systematic review

• Published in: Vaccine Vol. 32; no. 26; pp. 3162 - 3168
• Main Authors: Gröschel, Matthias I, Prabowo, Satria A, Cardona, Père-Joan, Stanford, John L, Werf, Tjip S van der
• Format: Journal Article
• Language: English
• Published: Kidlington Elsevier Ltd 30.05.2014; Elsevier; Elsevier Limited
• Subjects: Allergy and Immunology; Animals; Applied microbiology; Biological and medical sciences; Candidates; Clinical trials; Clinical Trials as Topic; Drug dosages; Drug resistance; Fundamental and applied biological sciences. Psychology; Humans; Immunotherapy; Infections; M. indicus pranii; M. smegmatis; Microbiology; Mycobacterium vaccae; RUTI; Studies; Systematic review; Therapeutic vaccine; Tuberculosis; Tuberculosis - prevention & control; Tuberculosis Vaccines - therapeutic use; V5 immunitor; Vaccines; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects); Vaccines, Inactivated - therapeutic use; Mycobacterium vaccae; Tuberculosis; Therapeutic vaccine; Immunotherapy; M. smegmatis; M. indicus pranii; Systematic review; V5 immunitor; RUTI; Taxonomy; Review; Mycobacteriales; Mycobacteriaceae; Bacteria; Actinomycetes
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2014.03.047

Highlights • We identified 5 potential therapeutic TB vaccines—Mycobacterium vaccae, RUTI, Mycobacterium smegmatis, Mycobacterium indicus pranii and V5. • M. vaccae and RUTI appeared most advanced, with most safety data in humans for M. vaccae. • Addition of therapeutic vaccine candidates in MDR-TB treatment should be tested for safety and efficacy in clinical trials. • Testing TB vaccine candidate products in TB patients provides a novel platform for TB vaccine development. • New clinical trial research platforms need to be developed to further test current and future TB vaccine product candidates.